scholarly journals Breast Density and Risk of Invasive Breast Cancer among Older Women Undergoing Mammography: The Breast Cancer Surveillance Consortium Cohort Study

2018 ◽  
Vol 27 (3) ◽  
pp. 352.2-352
Author(s):  
D Braithwaite ◽  
DL Miglioretti ◽  
W Zhu ◽  
J Demb ◽  
A Trentham-Dietz ◽  
...  
BMJ Open ◽  
2020 ◽  
Vol 10 (5) ◽  
pp. e035395 ◽  
Author(s):  
Yasmin Jauhari ◽  
Melissa Ruth Gannon ◽  
David Dodwell ◽  
Kieran Horgan ◽  
Karen Clements ◽  
...  

ObjectivesStudies that use national datasets to evaluate the management of older women with breast cancer are often constrained by a lack of information on patient fitness. This study constructed a frailty index for use with secondary care administrative records and evaluated its ability to improve models of treatment patterns and overall survival in women with breast cancer.DesignRetrospective cohort study.ParticipantsWomen aged ≥50 years with oestrogen receptor (ER) positive early invasive breast cancer diagnosed between 2014 and 2017 in England.MethodsThe secondary care administrative records frailty (SCARF) index was based on the cumulative deficit model of frailty, using International Statistical Classification of Diseases, Injuries and Causes of Death, 10th revision codes to define a set of deficits. The index was applied to administrative records that were linked to national cancer registry datasets. The ability of the SCARF index to improve the performance of regression models to explain observed variation in the rate of surgery and overall survival was evaluated using Harrell’s c-statistic and decision curve analysis. External validation was performed on a dataset of similar women diagnosed in Wales.ResultsThe SCARF index captured 32 deficits that cover functional impairment, geriatric syndromes, problems with nutrition, cognition and mood, and medical comorbidities. In the English dataset (n=67 925), the prevalence of frailty in women aged 50–69, 70–79 and ≥80 years was 15%, 28% and 47%, respectively. Adding a frailty measure to regression models containing age, tumour characteristics and comorbidity improved their ability to: (1) discriminate between whether a woman was likely to have surgery and (2) predict overall survival. Similar results were obtained when the models were applied to the Welsh cohort (n=4 230).ConclusionThe SCARF index provides a simple and consistent method to identify frailty in population level data and could help describe differences in breast cancer treatments and outcomes.


2018 ◽  
Vol 178 (4) ◽  
pp. 494 ◽  
Author(s):  
Dejana Braithwaite ◽  
Diana L. Miglioretti ◽  
Weiwei Zhu ◽  
Joshua Demb ◽  
Amy Trentham-Dietz ◽  
...  

2019 ◽  
Vol 111 (6) ◽  
pp. 629-632 ◽  
Author(s):  
B L Sprague ◽  
K Kerlikowske ◽  
E J A Bowles ◽  
G H Rauscher ◽  
C I Lee ◽  
...  

2019 ◽  
Vol 112 (6) ◽  
pp. 599-606 ◽  
Author(s):  
Joshua Demb ◽  
Linn Abraham ◽  
Diana L Miglioretti ◽  
Brian L Sprague ◽  
Ellen S O’Meara ◽  
...  

Abstract Background Potential benefits of screening mammography among women ages 75 years and older remain unclear. Methods We evaluated 10-year cumulative incidence of breast cancer and death from breast cancer and other causes by Charlson Comorbidity Index (CCI) and age in the Medicare-linked Breast Cancer Surveillance Consortium (1999–2010) cohort of 222 088 women with no less than 1 screening mammogram between ages 66 and 94 years. Results During median follow-up of 107 months, 7583 were diagnosed with invasive breast cancer and 1742 with ductal carcinoma in situ; 471 died from breast cancer and 42 229 from other causes. The 10-year cumulative incidence of invasive breast cancer did not change with increasing CCI but decreased slightly with age: ages 66–74 years (CCI0 = 4.0% [95% CI = 3.9% to 4.2%] vs CCI  ≥ 2 = 3.9% [95% CI = 3.5% to 4.3%]); ages 75–84 years (CCI0 = 3.7% [95% CI = 3.5% to 3.9%] vs CCI  ≥ 2 = 3.4% [95% CI = 2.9% to 3.9%]); and ages 85–94 years (CCI0 = 2.7% [95% CI = 2.3% to 3.1%] vs CCI  ≥ 2 = 2.1% [95% CI = 1.3% to 3.0%]). The 10-year cumulative incidence of other-cause death increased with increasing CCI and age: ages 66–74 years (CCI0 = 10.4% [95% CI = 10.3 to 10.7%] vs CCI ≥ 2 = 43.4% [95% CI = 42.2% to 44.4%]), ages 75–84 years (CCI0 = 29.8% [95% CI = 29.3% to 30.2%] vs CCI ≥ 2 = 61.7% [95% CI = 60.2% to 63.3%]), and ages 85 to 94 years (CCI0 = 60.3% [95% CI = 59.1% to 61.5%] vs CCI  ≥ 2 = 84.8% [95% CI = 82.5% to 86.9%]). The 10-year cumulative incidence of breast cancer death was small and did not vary by age: ages 66–74 years = 0.2% (95% CI = 0.2% to 0.3%), ages 75–84 years = 0.29% (95% CI = 0.25% to 0.34%), and ages 85 to 94 years = 0.3% (95% CI = 0.2% to 0.4%). Conclusions Cumulative incidence of other-cause death was many times higher than breast cancer incidence and death, depending on comorbidity and age. Hence, older women with increased comorbidity may experience diminished benefit from continued screening.


Cancer ◽  
2015 ◽  
Vol 121 (9) ◽  
pp. 1369-1378 ◽  
Author(s):  
Kimberly H. Allison ◽  
Linn A. Abraham ◽  
Donald L. Weaver ◽  
Anna N. A. Tosteson ◽  
Heidi D. Nelson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document